## David Dingli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1186019/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Improved survival in multiple myeloma and the impact of novel therapies. Blood, 2008, 111, 2516-2520.	1.4	2,022
2	Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia, 2014, 28, 1122-1128.	7.2	1,128
3	Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements. Journal of Clinical Oncology, 2012, 30, 989-995.	1.6	837
4	Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma. New England Journal of Medicine, 2019, 381, 727-738.	27.0	460
5	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clinic Proceedings, 2013, 88, 360-376.	3.0	440
6	Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. Mayo Clinic Proceedings, 2009, 84, 1095-1110.	3.0	389
7	Genetic Progression and the Waiting Time to Cancer. PLoS Computational Biology, 2007, 3, e225.	3.2	337
8	Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood, 2004, 103, 1641-1646.	1.4	306
9	Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology, 2009, 27, 5008-5014.	1.6	286
10	Biomedical System Dynamics to Improve Anemia Control With Darbepoetin Alfa in Long-Term Hemodialysis Patients. Mayo Clinic Proceedings, 2014, 89, 87-94.	3.0	285
11	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood, 2017, 129, 2111-2119.	1.4	249
12	Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy. Mayo Clinic Proceedings, 2014, 89, 926-933.	3.0	240
13	Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood, 2012, 119, 2100-2105.	1.4	218
14	Successful Therapy Must Eradicate Cancer Stem Cells. Stem Cells, 2006, 24, 2603-2610.	3.2	216
15	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis. Journal of Clinical Oncology, 2013, 31, 4319-4324.	1.6	193
16	A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia, 2007, 21, 529-534.	7.2	191
17	Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia, 2010, 24, 1934-1939.	7.2	182
18	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 2018, 8, 59.	6.2	171

#	Article	IF	CITATIONS
19	Unexplained Pulmonary Hypertension in Chronic Myeloproliferative Disorders. Chest, 2001, 120, 801-808.	0.8	168
20	Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score. Mayo Clinic Proceedings, 2011, 86, 12-18.	3.0	164
21	Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplantation, 2013, 48, 557-561.	2.4	158
22	Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood, 2006, 108, 1979-1983.	1.4	152
23	Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 4529-4535.	1.6	147
24	Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood, 2012, 119, 5397-5404.	1.4	144
25	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology, 2018, 36, 859-866.	1.6	140
26	IAP antagonists induce anti-tumor immunity in multiple myeloma. Nature Medicine, 2016, 22, 1411-1420.	30.7	133
27	Systemic amyloidosis from A (AA) to T (ATTR): a review. Journal of Internal Medicine, 2021, 289, 268-292.	6.0	133
28	Modeling of cancer virotherapy with recombinant measles viruses. Journal of Theoretical Biology, 2008, 252, 109-122.	1.7	131
29	Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. American Journal of Hematology, 2008, 83, 614-617.	4.1	123
30	Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia, 2017, 31, 2791-2798.	7.2	120
31	Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood, 2012, 119, 4860-4867.	1.4	119
32	Preclinical Pharmacology and Toxicology of Intravenous MV-NIS, an Oncolytic Measles Virus Administered With or Without Cyclophosphamide. Clinical Pharmacology and Therapeutics, 2007, 82, 700-710.	4.7	117
33	Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2017, 92, 578-598.	3.0	115
34	Mathematical modeling of cancer radiovirotherapy. Mathematical Biosciences, 2006, 199, 55-78.	1.9	114
35	Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Therapy, 2010, 17, 550-558.	4.6	112
36	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood, 2014, 124, 907-912.	1.4	111

#	Article	IF	CITATIONS
37	Diagnosis and Management of Waldenström Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	7.1	110
38	Early versus delayed autologous transplantation after immunomodulatory agentsâ€based induction therapy in patients with newly diagnosed multiple myeloma. Cancer, 2012, 118, 1585-1592.	4.1	106
39	Treatment of Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2015, 90, 1054-1081.	3.0	106
40	(A)Symmetric Stem Cell Replication and Cancer. PLoS Computational Biology, 2007, 3, e53.	3.2	104
41	Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia, 2011, 25, 689-696.	7.2	104
42	Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells. British Journal of Cancer, 2009, 101, 1130-1136.	6.4	101
43	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. Journal of Clinical Oncology, 2018, 36, 1323-1329.	1.6	100
44	Proteasome inhibitor associated thrombotic microangiopathy. American Journal of Hematology, 2016, 91, E348-52.	4.1	95
45	Genetically targeted radiotherapy for multiple myeloma. Blood, 2003, 102, 489-496.	1.4	92
46	Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits. Mayo Clinic Proceedings, 2015, 90, 587-596.	3.0	92
47	Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia, 2017, 31, 1562-1569.	7.2	92
48	Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer Journal, 2018, 8, 26.	6.2	92
49	Compartmental Architecture and Dynamics of Hematopoiesis. PLoS ONE, 2007, 2, e345.	2.5	91
50	Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative. Mayo Clinic Proceedings, 2008, 83, 1131-1135.	3.0	90
51	Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2015, 5, e296-e296.	6.2	90
52	Stochastic Dynamics of Hematopoietic Tumor Stem Cells. Cell Cycle, 2007, 6, 461-466.	2.6	88
53	Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia, 2016, 30, 2208-2213.	7.2	87
54	Allometric Scaling of the Active Hematopoietic Stem Cell Pool across Mammals. PLoS ONE, 2006, 1, e2.	2.5	86

#	Article	IF	CITATIONS
55	How we manage autologous stem cell transplantation for patients with multiple myeloma. Blood, 2014, 124, 882-890.	1.4	85
56	In vivo imaging and tumor therapy with the sodium iodide symporter. Journal of Cellular Biochemistry, 2003, 90, 1079-1086.	2.6	81
57	Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer Journal, 2015, 5, e364-e364.	6.2	81
58	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplantation, 2019, 54, 353-367.	2.4	81
59	Reconstructing the in vivo dynamics of hematopoietic stem cells from telomere length distributions. ELife, 2015, 4, .	6.0	81
60	Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Receiving Stem Cell Transplantation for Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 6, 384-388.	1.4	79
61	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. American Journal of Hematology, 2015, 90, 181-186.	4.1	76
62	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. American Journal of Hematology, 2016, 91, 1123-1128.	4.1	76
63	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. American Journal of Hematology, 2017, 92, 668-673.	4.1	75
64	Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center Bone Marrow Transplantation, 2013, 48, 1302-1307.	2.4	74
65	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2017, 92, 908-917.	3.0	72
66	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia, 2019, 33, 531-536.	7.2	72
67	Nâ€terminal fragment of the typeâ€B natriuretic peptide (NTâ€proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2016, 91, 1129-1134.	4.1	71
68	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Annals of Hematology, 2018, 97, 1417-1425.	1.8	71
69	Quantitative Molecular Imaging of Viral Therapy for Pancreatic Cancer Using an Engineered Measles Virus Expressing the Sodium-Iodide Symporter Reporter Gene. American Journal of Roentgenology, 2009, 192, 279-287.	2.2	70
70	Dynamics of Mutant Cells in Hierarchical Organized Tissues. PLoS Computational Biology, 2011, 7, e1002290.	3.2	70
71	Sodium Iodide Symporter ( <i>NIS</i> )-Mediated Radiovirotherapy for Pancreatic Cancer. American Journal of Roentgenology, 2010, 195, 341-349.	2.2	69
72	The ecology of cancer from an evolutionary game theory perspective. Interface Focus, 2014, 4, 20140019.	3.0	68

#	Article	IF	CITATIONS
73	Natural history of t(11;14) multiple myeloma. Leukemia, 2018, 32, 131-138.	7.2	67
74	Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood, 2006, 107, 3384-3388.	1.4	64
75	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia, 2018, 32, 2240-2249.	7.2	64
76	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer Journal, 2018, 8, 116.	6.2	64
77	High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart, 2014, 100, 383-388.	2.9	63
78	Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia, 2017, 31, 130-135.	7.2	63
79	Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer Journal, 2015, 5, e310-e310.	6.2	62
80	Combined I-124 Positron Emission Tomography/Computed Tomography Imaging of NIS Gene Expression in Animal Models of Stably Transfected and Intravenously Transfected Tumor. Molecular Imaging and Biology, 2006, 8, 16-23.	2.6	61
81	Dynamics of multiple myeloma tumor therapy with a recombinant measles virus. Cancer Gene Therapy, 2009, 16, 873-882.	4.6	60
82	Second auto-SCT for treatment of relapsed multiple myeloma. Bone Marrow Transplantation, 2013, 48, 568-573.	2.4	59
83	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry–Verified Typing. Mayo Clinic Proceedings, 2019, 94, 472-483.	3.0	59
84	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer Journal, 2020, 10, 82.	6.2	59
85	Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer, 2006, 106, 1985-1989.	4.1	58
86	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Advances, 2020, 4, 3509-3519.	5.2	58
87	Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial. American Journal of Hematology, 2011, 86, 640-645.	4.1	57
88	Longâ€ŧerm outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. American Journal of Hematology, 2016, 91, 585-589.	4.1	57
89	Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. Leukemia, 2016, 30, 633-639.	7.2	57
90	Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 86-92.	3.0	57

#	Article	IF	CITATIONS
91	<i>MYD88</i> mutation status does not impact overall survival in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 187-194.	4.1	57
92	Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia. Cancer, 2006, 106, 623-630.	4.1	56
93	Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer Journal, 2016, 6, e454-e454.	6.2	56
94	Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. Haematologica, 2010, 95, 900-907.	3.5	55
95	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood, 2017, 130, 1198-1204.	1.4	54
96	Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells. Leukemia, 2019, 33, 2695-2709.	7.2	52
97	Autologous stem cell transplant for multiple myeloma patients 70 years or older. Bone Marrow Transplantation, 2016, 51, 1449-1455.	2.4	51
98	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. Circulation: Cardiovascular Imaging, 2018, 11, e006588.	2.6	51
99	Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates. Haemophilia, 2002, 8, 629-634.	2.1	50
100	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood, 2017, 129, 82-87.	1.4	50
101	Focal and Segmental Glomerulosclerosis and Plasma Cell Proliferative Disorders. American Journal of Kidney Diseases, 2005, 46, 278-282.	1.9	49
102	Efficacy of VDT PACEâ€like regimens in treatment of relapsed/refractory multiple myeloma. American Journal of Hematology, 2018, 93, 179-186.	4.1	49
103	A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. British Journal of Haematology, 2012, 156, 326-333.	2.5	48
104	Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia. British Journal of Haematology, 2005, 130, 229-232.	2.5	47
105	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. Biology of Blood and Marrow Transplantation, 2017, 23, 598-605.	2.0	47
106	Neutral evolution in paroxysmal nocturnal hemoglobinuria. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18496-18500.	7.1	46
107	A deterministic model for the occurrence and dynamics of multiple mutations in hierarchically organized tissues. Journal of the Royal Society Interface, 2013, 10, 20130349.	3.4	45
108	Induction therapy preâ€autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. American Journal of Hematology, 2016, 91, 984-988.	4.1	45

#	Article	IF	CITATIONS
109	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Annals of Medicine, 2017, 49, 545-551.	3.8	45
110	Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia, 2018, 32, 729-735.	7.2	44
111	Systemic Immunoglobulin Light Chain Amyloidosis–Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. Mayo Clinic Proceedings, 2016, 91, 1354-1361.	3.0	43
112	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia, 2022, 36, 801-808.	7.2	43
113	Schnitzler syndrome: an under-diagnosed clinical entity. Haematologica, 2013, 98, 1581-1585.	3.5	42
114	Optimization of Virotherapy for Cancer. Bulletin of Mathematical Biology, 2010, 72, 469-489.	1.9	41
115	Betaâ€blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. American Journal of Hematology, 2017, 92, 50-55.	4.1	41
116	Impact of acquired del(17p) in multiple myeloma. Blood Advances, 2019, 3, 1930-1938.	5.2	41
117	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. British Journal of Haematology, 2020, 188, 394-403.	2.5	41
118	Relationship Between Depth of Response and Outcome in Multiple Myeloma. Journal of Clinical Oncology, 2007, 25, 4933-4937.	1.6	40
119	Tenâ€year survivors in AL amyloidosis: characteristics and treatment pattern. British Journal of Haematology, 2019, 187, 588-594.	2.5	40
120	Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter. Biochemical and Biophysical Research Communications, 2004, 325, 157-166.	2.1	39
121	Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. Blood Cancer Journal, 2017, 7, e528-e528.	6.2	39
122	Promising preclinical activity of 2-methoxyestradiol in multiple myeloma. Clinical Cancer Research, 2002, 8, 3948-54.	7.0	39
123	Myelofibrosis with Myeloid Metaplasia: New Developments in Pathogenesis and Treatment. Internal Medicine, 2004, 43, 540-547.	0.7	38
124	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. American Journal of Hematology, 2015, 90, 981-985.	4.1	38
125	Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer Journal, 2016, 6, e512-e512.	6.2	38
126	Myelomatous Involvement of the Central Nervous System. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 644-654.	0.4	38

#	Article	IF	CITATIONS
127	Natural history of multiple myeloma with de novo del(17p). Blood Cancer Journal, 2019, 9, 32.	6.2	38
128	Pyoderma gangrenosum in hematologic malignancies: A systematic review. Journal of the American Academy of Dermatology, 2020, 82, 1346-1359.	1.2	38
129	Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin lightâ€chain amyloidosis. Cancer, 2016, 122, 2197-2205.	4.1	37
130	Enhancing the Râ€ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. American Journal of Hematology, 2020, 95, 310-315.	4.1	37
131	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. American Journal of Hematology, 2019, 94, 1020-1026.	4.1	36
132	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia, 2019, 33, 527-531.	7.2	36
133	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer Journal, 2020, 10, 55.	6.2	36
134	Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy. British Journal of Cancer, 2016, 115, 195-202.	6.4	35
135	A promising approach for treatment of tumor-induced bone diseases: Utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone, 2010, 47, 12-22.	2.9	34
136	Impact of MYD88 <sup>L265P</sup> mutation status on histological transformation of Waldenström Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	4.1	33
137	Interaction of measles virus vectors with Auger electron emitting radioisotopes. Biochemical and Biophysical Research Communications, 2005, 337, 22-29.	2.1	32
138	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. American Journal of Hematology, 2014, 89, 1051-1054.	4.1	32
139	Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. Leukemia, 2016, 30, 1079-1085.	7.2	32
140	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clinical Cancer Research, 2020, 26, 6581-6588.	7.0	32
141	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clinic Proceedings, 2021, 96, 1546-1577.	3.0	32
142	On the Origin of Multiple Mutant Clones in Paroxysmal Nocturnal Hemoglobinuria. Stem Cells, 2007, 25, 3081-3084.	3.2	31
143	On the dynamics of neutral mutations in a mathematical model for a homogeneous stem cell population. Journal of the Royal Society Interface, 2013, 10, 20120810.	3.4	31
144	Soluble suppression of tumorigenicity 2 (s <scp>ST</scp> 2), but not galactinâ€3, adds to prognostication in patients with systemic <scp>AL</scp> amyloidosis independent of <scp>NT</scp> â€pro <scp>BNP</scp> and troponin <scp>T</scp> . American Journal of Hematology, 2015, 90, 524-528.	4.1	31

#	Article	IF	CITATIONS
145	Chronic Myeloid Leukemia: Origin, Development, Response to Therapy, and Relapse. Clinical Leukemia, 2008, 2, 133-139.	0.2	30
146	Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis. Neurology, 2010, 74, 913-918.	1.1	30
147	Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Leukemia, 2013, 27, 2062-2066.	7.2	30
148	Imaging findings in 22 cases of Schnitzler syndrome: characteristic para-articular osteosclerosis, and the "hot knees―sign differential diagnosis. Skeletal Radiology, 2014, 43, 905-915.	2.0	30
149	Clinical characteristics and outcomes in biclonal gammopathies. American Journal of Hematology, 2016, 91, 473-475.	4.1	30
150	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Leukemia, 2017, 31, 92-99.	7.2	30
151	Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. Bone Marrow Transplantation, 2017, 52, 1126-1132.	2.4	30
152	The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transplantation, 2017, 52, 34-40.	2.4	30
153	A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 21.	6.2	30
154	Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. Haematologica, 2017, 102, 1439-1445.	3.5	29
155	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer Journal, 2018, 8, 125.	6.2	29
156	HIV-1 Activation of Innate Immunity Depends Strongly on the Intracellular Level of TREX1 and Sensing of Incomplete Reverse Transcription Products. Journal of Virology, 2018, 92, .	3.4	29
157	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia, 2020, 34, 1135-1143.	7.2	29
158	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia, 2018, 32, 1811-1815.	7.2	28
159	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. Leukemia, 2019, 33, 790-794.	7.2	28
160	"Real-life―data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience. Blood Cancer Journal, 2021, 11, 196.	6.2	28
161	Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors. Gene Therapy, 2012, 19, 279-287.	4.5	27
162	Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling. Gene Therapy, 2012, 19, 543-549.	4.5	27

#	Article	IF	CITATIONS
163	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. Leukemia, 2018, 32, 712-718.	7.2	27
164	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. Blood Cancer Journal, 2020, 10, 20.	6.2	26
165	Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation Blood, 2012, 120, 3138-3138.	1.4	26
166	The emergence of tumor metastases. Cancer Biology and Therapy, 2007, 6, 383-390.	3.4	25
167	Imatinib and Type 2 Diabetes. Endocrine Practice, 2007, 13, 126-130.	2.1	25
168	Dynamics of Leukemia Stem-like Cell Extinction in Acute Promyelocytic Leukemia. Cancer Research, 2014, 74, 5386-5396.	0.9	25
169	Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. Leukemia, 2015, 29, 2033-2038.	7.2	25
170	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrology Dialysis Transplantation, 2016, 31, 1284-1289.	0.7	25
171	Dexamethasone, rituximab and cyclophosphamide for relapsedÂand/or refractory and treatmentâ€naÃ⁻ve patients with Waldenstrom macroglobulinemia. British Journal of Haematology, 2017, 179, 98-105.	2.5	25
172	Efficacy of daratumumabâ€based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. American Journal of Hematology, 2017, 92, 1146-1155.	4.1	25
173	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 13-16.	3.0	25
174	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer Journal, 2021, 11, 50.	6.2	25
175	Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM). Blood, 2014, 124, 304-304.	1.4	25
176	Ontogenic growth of the haemopoietic stem cell pool in humans. Proceedings of the Royal Society B: Biological Sciences, 2007, 274, 2497-2501.	2.6	24
177	Progenitor cell selfâ€renewal and cyclic neutropenia. Cell Proliferation, 2009, 42, 330-338.	5.3	24
178	Somatic mutations and the hierarchy of hematopoiesis. BioEssays, 2010, 32, 1003-1008.	2.5	24
179	Should tissue structure suppress or amplify selection to minimize cancer risk?. Biology Direct, 2016, 11, 41.	4.6	24
180	Detecting truly clonal alterations from multi-region profiling of tumours. Scientific Reports, 2017, 7, 44991.	3.3	24

#	Article	IF	CITATIONS
181	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. American Journal of Hematology, 2017, 92, 549-554.	4.1	24
182	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 1384-1393.	4.1	24
183	Modeling the architecture and dynamics of hematopoiesis. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2010, 2, 235-244.	6.6	23
184	Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. European Journal of Haematology, 2014, 92, 485-490.	2.2	23
185	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Advances, 2018, 2, 769-776.	5.2	23
186	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leukemia Research, 2016, 44, 32-39.	0.8	22
187	Comparative analysis of staging systems in AL amyloidosis. Leukemia, 2019, 33, 811-814.	7.2	22
188	A critical review of anagrelide therapy in essential thrombocythemia and related disorders. Leukemia and Lymphoma, 2005, 46, 641-650.	1.3	21
189	In silico evolutionary dynamics of tumour virotherapy. Integrative Biology (United Kingdom), 2010, 2, 41-45.	1.3	21
190	Delineation of the timing of second-line therapy post–autologous stem cell transplant in patients with AL amyloidosis. Blood, 2017, 130, 1578-1584.	1.4	21
191	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 2127-2132.	2.0	21
192	How many samples are needed to infer truly clonal mutations from heterogenous tumours?. BMC Cancer, 2019, 19, 403.	2.6	21
193	Implications of detecting serum monoclonal protein by MASSâ€fix following stem cell transplantation in multiple myeloma. British Journal of Haematology, 2021, 193, 380-385.	2.5	21
194	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. American Journal of Hematology, 2021, 96, 1131-1136.	4.1	21
195	Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study. Blood, 2016, 128, 491-491.	1.4	21
196	Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. Haematologica, 2005, 90, 1650-4.	3.5	21
197	Multiple mutant clones in blood rarely coexist. Physical Review E, 2008, 77, 021915.	2.1	20
198	Stochastic dynamics and the evolution of mutations in stem cells. BMC Biology, 2011, 9, 41.	3.8	20

#	Article	IF	CITATIONS
199	Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. Bone Marrow Transplantation, 2014, 49, 201-205.	2.4	20
200	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2019, 25, e108-e111.	2.0	20
201	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. Leukemia, 2019, 33, 730-738.	7.2	20
202	"Direct to Drug―screening as a precision medicine tool in multiple myeloma. Blood Cancer Journal, 2020, 10, 54.	6.2	20
203	Utility and prognostic value of <sup>18</sup> Fâ€FDG positron emission tomographyâ€computed tomography scans in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 1518-1523.	4.1	19
204	In vitro and in silico multidimensional modeling of oncolytic tumor virotherapy dynamics. PLoS Computational Biology, 2019, 15, e1006773.	3.2	19
205	Characteristics of late transplantâ€associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2020, 95, 1170-1179.	4.1	19
206	The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Annals of Hematology, 2022, 101, 251-263.	1.8	19
207	Acquired hematopoietic stem-cell disorders and mammalian size. Blood, 2007, 110, 4120-4122.	1.4	18
208	Cyclic neutropenia in mammals. American Journal of Hematology, 2008, 83, 920-921.	4.1	18
209	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. American Journal of Hematology, 2015, 90, 888-891.	4.1	18
210	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer Journal, 2018, 8, 70.	6.2	18
211	A Patient With Hereditary ATTR and a Novel AGel p.Ala578Pro Amyloidosis. Mayo Clinic Proceedings, 2018, 93, 1678-1682.	3.0	18
212	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. Blood Cancer Journal, 2020, 10, 4.	6.2	18
213	Evolutionary Dynamics of Chronic Myeloid Leukemia. Genes and Cancer, 2010, 1, 309-315.	1.9	17
214	Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. Bone Marrow Transplantation, 2016, 51, 1156-1158.	2.4	17
215	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. American Journal of Hematology, 2019, 94, E141-E143.	4.1	17
216	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. American Journal of Hematology, 2020, 95, 1280-1287.	4.1	17

#	Article	IF	CITATIONS
217	Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM. Blood, 2018, 132, 598-598.	1.4	17
218	A Microenvironment Based Model of Antimitotic Therapy of Gompertzian Tumor Growth. Bulletin of Mathematical Biology, 2007, 69, 1691-1708.	1.9	16
219	Dynamics of haemopoiesis across mammals. Proceedings of the Royal Society B: Biological Sciences, 2008, 275, 2389-2392.	2.6	16
220	Modelling hematopoiesis in health and disease. Mathematical and Computer Modelling, 2011, 53, 1546-1557.	2.0	16
221	Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. Leukemia and Lymphoma, 2017, 58, 308-315.	1.3	16
222	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. American Journal of Hematology, 2017, 92, 435-440.	4.1	16
223	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. Mayo Clinic Proceedings, 2018, 93, 56-58.	3.0	16
224	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. Blood Cancer Journal, 2018, 8, 106.	6.2	16
225	<i>In Vivo</i> Estimation of Oncolytic Virus Populations within Tumors. Cancer Research, 2018, 78, 5992-6000.	0.9	16
226	The invasion of de-differentiating cancer cells into hierarchical tissues. PLoS Computational Biology, 2019, 15, e1007167.	3.2	16
227	Preclinical development of CD126 CAR-T cells with broad antitumor activity. Blood Cancer Journal, 2021, 11, 3.	6.2	16
228	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. Mayo Clinic Proceedings, 2021, 96, 677-687.	3.0	16
229	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients. Blood, 2012, 120, 201-201.	1.4	16
230	Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma Blood, 2012, 120, 2973-2973.	1.4	16
231	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. Mayo Clinic Proceedings, 2019, 94, 455-464.	3.0	16
232	Serum M-spike and transplant outcome in patients with multiple myeloma. Cancer Science, 2007, 98, 1035-1040.	3.9	15
233	Cyclic neutropenia in animals. American Journal of Hematology, 2009, 84, 258-258.	4.1	15
234	Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. Journal of Internal Medicine, 2017, 281, 611-619.	6.0	15

#	Article	IF	CITATIONS
235	Elevation of serum lactate dehydrogenase in <scp>AL</scp> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. British Journal of Haematology, 2017, 178, 888-895.	2.5	15
236	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. British Journal of Haematology, 2018, 182, 71-77.	2.5	15
237	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. American Journal of Hematology, 2019, 94, 751-756.	4.1	15
238	Revisiting complete response in light chain amyloidosis. Leukemia, 2020, 34, 1472-1475.	7.2	15
239	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 596-601.	0.4	15
240	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. Bone Marrow Transplantation, 2021, 56, 1144-1150.	2.4	15
241	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2018, 24, 2360-2364.	2.0	14
242	Evolutionary dynamics of paroxysmal nocturnal hemoglobinuria. PLoS Computational Biology, 2018, 14, e1006133.	3.2	14
243	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. American Journal of Hematology, 2019, 94, 1066-1071.	4.1	14
244	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. American Journal of Hematology, 2020, 95, 4-9.	4.1	14
245	A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. Bone Marrow Transplantation, 2017, 52, 1372-1377.	2.4	13
246	Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. Leukemia, 2018, 32, 719-728.	7.2	13
247	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. Kidney International, 2021, 99, 707-715.	5.2	13
248	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone ( <scp>VRd</scp> ) as firstâ€line therapy in multiple myeloma. American Journal of Hematology, 2021, 96, 330-337.	4.1	13
249	Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas. Blood, 2019, 134, 3140-3140.	1.4	13
250	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 864-864.	1.4	13
251	Optimized Treatment Schedules for Chronic Myeloid Leukemia. PLoS Computational Biology, 2016, 12, e1005129.	3.2	13
252	Trend towards Improved Day 100 and 2-Year Survival After SCT for AL Amyloidosis: Outcomes Before and After 2006. Blood, 2010, 116, 3554-3554.	1.4	13

#	Article	IF	CITATIONS
253	Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. Blood Advances, 2022, 6, 2763-2772.	5.2	13
254	Reproductive fitness advantage of BCR–ABL expressing leukemia cells. Cancer Letters, 2010, 294, 43-48.	7.2	12
255	Monitoring the initial delivery of an oncolytic measles virus encoding the human sodium iodide symporter to solid tumors using contrastâ€enhanced computed tomography. Journal of Gene Medicine, 2012, 14, 590-597.	2.8	12
256	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. Blood Cancer Journal, 2020, 10, 124.	6.2	12
257	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. American Journal of Hematology, 2020, 95, 637-642.	4.1	12
258	Assessment of fixedâ€duration therapies for treatmentâ€naÃ⁻ve <scp>Waldenström</scp> macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	4.1	12
259	Disease outcomes and biomarkers of progression in smouldering Waldenstr¶m macroglobulinaemia. British Journal of Haematology, 2021, 195, 210-216.	2.5	12
260	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. Blood, 2013, 122, 407-407.	1.4	12
261	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia, 2022, 36, 873-876.	7.2	12
262	How best to use new therapies in multiple myeloma. Blood Reviews, 2010, 24, 91-100.	5.7	11
263	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). American Journal of Hematology, 2018, 93, 17-22.	4.1	11
264	InÂVivo Imaging of Oncolytic Measles Virus Propagation with Single-Cell Resolution. Molecular Therapy - Oncolytics, 2019, 12, 68-78.	4.4	11
265	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiâ€parametric flow cytometry method. American Journal of Hematology, 2019, 94, 424-430.	4.1	11
266	The allometry of chronic myeloid leukemia. Journal of Theoretical Biology, 2009, 259, 635-640.	1.7	10
267	Mutations in the Stalk Region of the Measles Virus Hemagglutinin Inhibit Syncytium Formation but Not Virus Entry. Journal of Virology, 2010, 84, 10913-10917.	3.4	10
268	Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 349-357.e2.	0.4	10
269	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. Haematologica, 2018, 103, 1229-1234.	3.5	10
270	Replicative cellular age distributions in compartmentalized tissues. Journal of the Royal Society Interface, 2018, 15, 20180272.	3.4	10

#	Article	IF	CITATIONS
271	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. American Journal of Hematology, 2020, 95, E8-E10.	4.1	10
272	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 304-304.	1.4	10
273	Ontogenic growth as the root of fundamental differences between childhood and adult cancer. Stem Cells, 2016, 34, 543-550.	3.2	9
274	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. Haematologica, 2016, 101, 1102-1109.	3.5	9
275	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2019, 54, 587-594.	2.4	9
276	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 101-102.	3.0	9
277	Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. Mayo Clinic Proceedings, 2019, 94, 1834-1839.	3.0	9
278	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2019, 54, 2039-2050.	2.4	9
279	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. Biology of Blood and Marrow Transplantation, 2019, 25, 1520-1525.	2.0	9
280	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. Bone Marrow Transplantation, 2019, 54, 1775-1779.	2.4	9
281	T-cell large granular lymphocytic leukemia and plasma cell disorders. Haematologica, 2019, 104, e108-e110.	3.5	9
282	Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)–Associated Lesions: A Case Series. American Journal of Kidney Diseases, 2022, 79, 202-216.	1.9	9
283	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 451-460.e2.	0.4	9
284	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). Blood Cancer Journal, 2021, 11, 158.	6.2	9
285	Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien. Blood, 2013, 122, 2151-2151.	1.4	9
286	Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. Blood Cancer Journal, 2017, 7, e569-e569.	6.2	8
287	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia, 2018, 32, 1421-1426.	7.2	8
288	Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 155-161.	2.4	8

#	Article	IF	CITATIONS
289	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. Biology of Blood and Marrow Transplantation, 2018, 24, 2157-2159.	2.0	8
290	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 53-56.	0.4	8
291	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Bone Marrow Transplantation, 2020, 55, 2132-2137.	2.4	8
292	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. Blood Cancer Journal, 2020, 10, 52.	6.2	8
293	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. Leukemia, 2021, 35, 1428-1437.	7.2	8
294	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. Leukemia, 2021, 35, 3604-3607.	7.2	8
295	Comparison of the current renal staging, progression and response criteria to predict renal survival in <scp>AL</scp> amyloidosis using a <scp>Mayo</scp> cohort. American Journal of Hematology, 2021, 96, 446-454.	4.1	8
296	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. Blood, 2015, 126, 3050-3050.	1.4	8
297	The Depth of Renal Response Strongly Predicts Overall Surival in Patients with AL Amyloidosis. Blood, 2011, 118, 2868-2868.	1.4	8
298	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer Journal, 2021, 11, 186.	6.2	8
299	Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes. Blood, 2020, 136, 44-45.	1.4	8
300	Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100. Leukemia, 2022, 36, 1429-1431.	7.2	8
301	Explaining the in vitro and in vivo differences in leukemia therapy. Cell Cycle, 2011, 10, 1540-1544.	2.6	7
302	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. Bone Marrow Transplantation, 2019, 54, 442-447.	2.4	7
303	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia, 2019, 33, 1268-1272.	7.2	7
304	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1077-1081.	2.4	7
305	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. Blood, 2012, 120, 3972-3972.	1.4	7
306	Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma. Blood, 2013, 122, 3210-3210.	1.4	7

#	Article	IF	CITATIONS
307	Flow Cytometric Detection of Circulating Myeloma Cells Pretransplant in Patients with Multiple Myeloma: A Simple Risk Stratification System Blood, 2005, 106, 1164-1164.	1.4	7
308	Kidney Transplant Outcomes of Patients With Multiple Myeloma. Kidney International Reports, 2022, 7, 752-762.	0.8	7
309	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia, 2022, 36, 1426-1428.	7.2	7
310	InÂvivoandinÂsilicostudies on single versus multiple transplants for multiple myeloma. Cancer Science, 2007, 98, 734-739.	3.9	6
311	Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia and Lymphoma, 2009, 50, 781-787.	1.3	6
312	Evolutionary dynamics of two related malignant plasma cell lines. Cell Cycle, 2010, 9, 3816-3821.	2.6	6
313	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. Transplantation and Cellular Therapy, 2021, 27, 770.e1-770.e7.	1.2	6
314	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma. Blood, 2019, 134, 4106-4106.	1.4	6
315	Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials Blood, 2009, 114, 615-615.	1.4	6
316	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). Blood, 2015, 126, 1774-1774.	1.4	6
317	Comparison of Troponin T and N-Terminal-Pro-Brain Natriuretic Peptides In Two Models of Treatment Related Mortality In AL Amyloidosis Patients Following Autologous Stem Cell Transplantation. Blood, 2010, 116, 3572-3572.	1.4	6
318	Prognostic significance of acquired 1q22 gain in multiple myeloma. American Journal of Hematology, 2021, , .	4.1	6
319	Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant. Bone Marrow Transplantation, 2022, 57, 803-809.	2.4	6
320	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). Blood Cancer Journal, 2022, 12, 62.	6.2	6
321	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. American Journal of Hematology, 2017, 92, E507-E512.	4.1	5
322	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. Bone Marrow Transplantation, 2020, 55, 1297-1304.	2.4	5
323	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. Bone Marrow Transplantation, 2021, 56, 928-935.	2.4	5
324	Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation. Kidney International Reports, 2021, 6, 857-864.	0.8	5

#	Article	IF	CITATIONS
325	Multistage feedback-driven compartmental dynamics of hematopoiesis. IScience, 2021, 24, 102326.	4.1	5
326	Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 355-360.	0.4	5
327	Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma. Blood, 2010, 116, 1964-1964.	1.4	5
328	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. Blood, 2015, 126, 4197-4197.	1.4	5
329	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. Blood, 2016, 128, 3337-3337.	1.4	5
330	Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM) Journal of Clinical Oncology, 2016, 34, 8002-8002.	1.6	5
331	Peripheral Blood Stem Cell Collection In Patients Undergoing Induction Therapy with Lenalidomide Based Regimens: Failure Rates and Salvage Approaches. Blood, 2010, 116, 2253-2253.	1.4	5
332	The Timing of Acute Renal Failure Strongly Affects Survival of Immunoglobulin Light Chain (AL) Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation,. Blood, 2011, 118, 4120-4120.	1.4	5
333	Characteristics and risk factors for thrombosis in <scp>POEMS</scp> syndrome: A retrospective evaluation of 230 patients. American Journal of Hematology, 2022, 97, 209-215.	4.1	5
334	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. American Journal of Hematology, 2022, , .	4.1	5
335	Emerging therapies for multiple myeloma. Oncology, 2009, 23, 407-15.	0.5	5
336	Genetic Targeting of Retroviral Vectors. , 2003, , 267-291.		4
337	Anagrelide: an update on its mechanisms of action and therapeutic potential. Expert Review of Anticancer Therapy, 2004, 4, 533-541.	2.4	4
338	Reply: Evolutionary game theory: lessons and limitations, a cancer perspective. British Journal of Cancer, 2009, 101, 2062-2063.	6.4	4
339	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 40-41.	3.0	4
340	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 183-188.	3.0	4
341	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. Bone Marrow Transplantation, 2018, 53, 326-333.	2.4	4
342	Implications and outcomes of MRDâ€negative multiple myeloma patients with immunofixation positivity. American Journal of Hematology, 2020, 95, E60-E62.	4.1	4

#	Article	lF	CITATIONS
343	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1402-1405.	2.0	4
344	Characterization and prognostic implication of delayed complete response in AL amyloidosis. European Journal of Haematology, 2021, 106, 354-361.	2.2	4
345	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. Blood, 2020, 136, 52-53.	1.4	4
346	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 36-37.	1.4	4
347	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 30-31.	1.4	4
348	Pre-Stem Cell Transplant Induction Therapy Does Not Affect Post-Transplant Survival In Light Chain (AL) Amyloidosis. Blood, 2010, 116, 370-370.	1.4	4
349	Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years,. Blood, 2011, 118, 3963-3963.	1.4	4
350	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). Blood, 2016, 128, 2968-2968.	1.4	4
351	Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. Blood, 2021, 138, 568-568.	1.4	4
352	Schnitzler syndrome: clinical features and histopathology. Pathology and Laboratory Medicine International, 2015, , 39.	0.2	3
353	Serum free light chain measurements to reduce 24â€h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. American Journal of Hematology, 2018, 93, 1207-1210.	4.1	3
354	Colon perforation in multiple myeloma patients – A complication of highâ€dose steroid treatment. Cancer Medicine, 2020, 9, 8895-8901.	2.8	3
355	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer Journal, 2020, 10, 95.	6.2	3
356	Venetoclax in a Patient With Light Chain Deposition Disease Secondary to MGRS That Progressed After Kidney Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e488-e491.	0.4	3
357	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. European Journal of Haematology, 2021, 106, 433-436.	2.2	3
358	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. Transplantation and Cellular Therapy, 2021, 27, 589.e1-589.e6.	1.2	3
359	Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study. Blood, 2019, 134, 1872-1872. 	1.4	3
360	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). Blood, 2020, 136, 12-13.	1.4	3

#	Article	IF	CITATIONS
361	Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma,. Blood, 2011, 118, 3981-3981.	1.4	3
362	Survival Outcomes Of Very Young (<40 years) Myeloma Patients. Blood, 2013, 122, 2136-2136.	1.4	3
363	Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. Blood, 2013, 122, 3119-3119.	1.4	3
364	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. Blood, 2015, 126, 3177-3177.	1.4	3
365	Thrombotic Microangiopathy in Multiple Myeloma. Blood, 2015, 126, 5317-5317.	1.4	3
366	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. Blood, 2016, 128, 3317-3317.	1.4	3
367	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. Blood, 2021, 138, 1639-1639.	1.4	3
368	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia, 2022, 36, 1058-1065.	7.2	3
369	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. Blood Cancer Journal, 2022, 12, 59.	6.2	3
370	Death by fusion for acute leukemia cells. Cancer Biology and Therapy, 2010, 9, 358-361.	3.4	2
371	Predictors of short-term survival in Waldenström Macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 2975-2979.	1.3	2
372	Outcomes of multiple myeloma patients with <scp>del 17p</scp> undergoing autologous stem cell transplantation. American Journal of Hematology, 2021, 96, E35-E38.	4.1	2
373	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. Leukemia and Lymphoma, 2021, 62, 316-322.	1.3	2
374	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. Leukemia and Lymphoma, 2021, 62, 3011-3018.	1.3	2
375	Quantitative imaging and dynamics of tumor therapy with viruses. FEBS Journal, 2021, 288, 6273-6285.	4.7	2
376	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. Blood, 2019, 134, 72-72.	1.4	2
377	A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome. Blood, 2019, 134, 1846-1846.	1.4	2
378	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. Blood, 2019, 134, 4386-4386.	1.4	2

#	Article	IF	CITATIONS
379	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. Blood, 2019, 134, 1905-1905.	1.4	2
380	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. Blood, 2020, 136, 48-49.	1.4	2
381	Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort. Blood, 2011, 118, 2942-2942.	1.4	2
382	Outcomes and Treatments of Relapsed AL Amyloidosis Following Stem Cell Transplant. Blood, 2012, 120, 1858-1858.	1.4	2
383	Genomics Of Familial Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood, 2013, 122, 2803-2803.	1.4	2
384	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. Blood, 2013, 122, 3117-3117.	1.4	2
385	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2972-2972.	1.4	2
386	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. Blood, 2018, 132, 3160-3160.	1.4	2
387	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. Blood, 2021, 138, 1750-1750.	1.4	2
388	Work Productivity Loss and Quality of Life in Paroxysmal Nocturnal Hemoglobinuria Among Patients Receiving C5 Inhibitors in the United States. Blood, 2020, 136, 3-3.	1.4	2
389	Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL). Blood, 2020, 136, 29-30.	1.4	2
390	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. American Journal of Hematology, 2022, , .	4.1	2
391	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation. Leukemia and Lymphoma, 2022, 63, 2422-2427.	1.3	2
392	Some Dynamic Aspects of Hematopoietic Stem Cells. Stem Cell Reviews and Reports, 2008, 4, 57-64.	5.6	1
393	Clinical Outcomes With and Without Sargramostim (GM-CSF) Post Autologous Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 43.	2.0	1
394	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 44-45.	3.0	1
395	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 274-277.	2.4	1
396	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 309.e1-309.e5.	1.2	1

#	Article	IF	CITATIONS
397	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. Blood, 2019, 134, 4334-4334.	1.4	1
398	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2020, 136, 7-8.	1.4	1
399	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. Blood, 2020, 136, 22-23.	1.4	1
400	Immunoglobulin Free Light Chains at Diagnosis: Predictors of Progression and Survival in Solitary Plasmacytoma of Bone Blood, 2005, 106, 5080-5080.	1.4	1
401	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (clg-FISH) Blood, 2007, 110, 2477-2477.	1.4	1
402	Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation Blood, 2009, 114, 956-956.	1.4	1
403	Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicitng Outcome In Over 400 Patients. Blood, 2010, 116, 3557-3557.	1.4	1
404	Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease. Blood, 2010, 116, 863-863.	1.4	1
405	The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. Blood, 2011, 118, 2887-2887.	1.4	1
406	Survival Outcome of Young Multiple Myeloma (MM) Patients in the Era of Novel Therapies. Blood, 2011, 118, 2950-2950.	1.4	1
407	A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM). Blood, 2011, 118, 3095-3095.	1.4	1
408	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis Blood, 2012, 120, 946-946.	1.4	1
409	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. Blood, 2013, 122, 3095-3095.	1.4	1
410	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. Blood, 2015, 126, 1830-1830.	1.4	1
411	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 2082-2082.	1.4	1
412	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. Blood, 2016, 128, 3272-3272.	1.4	1
413	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. Blood, 2016, 128, 3444-3444.	1.4	1
414	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. Blood, 2016, 128, 4627-4627.	1.4	1

#	Article	IF	CITATIONS
415	Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression Journal of Clinical Oncology, 2016, 34, 8015-8015.	1.6	1
416	Oncolytic virotherapy - in vivo veritas. Oncotarget, 2018, 9, 36254-36255.	1.8	1
417	Improvement In Renal Function In Newly Diagnosed Myeloma Improves Survival, but Still Remains Inferior to Those with Normal Renal Function. Blood, 2010, 116, 2970-2970.	1.4	1
418	A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) Amyloidosis. Blood, 2010, 116, 987-987.	1.4	1
419	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naÃ <sup>-</sup> ve (TN) Waldenström macroglobulinemia (WM) Journal of Clinical Oncology, 2016, 34, 7552-7552.	1.6	1
420	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. Blood, 2018, 132, 1606-1606.	1.4	1
421	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2884-2884.	1.4	1
422	T Cell Large Granular Lymphocytic Leukemia and Co-Existing Plasma Cell Disorders. Blood, 2018, 132, 5368-5368.	1.4	1
423	Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. Blood, 2018, 132, 4152-4152.	1.4	1
424	Patient-Reported Outcome Driven Case Management System for Hematology — a Prospective Study. Blood, 2018, 132, 719-719.	1.4	1
425	Therapy for relapsed multiple myeloma. Panminerva Medica, 2018, 60, 174-184.	0.8	1
426	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. Blood, 2019, 134, 3171-3171.	1.4	1
427	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. Blood, 2019, 134, 1800-1800.	1.4	1
428	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. Blood, 2019, 134, 5490-5490.	1.4	1
429	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. Blood, 2021, 138, 819-819.	1.4	1
430	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. Blood, 2021, 138, 3760-3760.	1.4	1
431	Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. Blood, 2021, 138, 3774-3774.	1.4	1
432	Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART. Blood, 2021, 138, 3838-3838.	1.4	1

#	Article	IF	CITATIONS
433	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. Blood, 2020, 136, 31-32.	1.4	1
434	Successful Cancer Treatment: Eradication of Cancer Stem Cells. , 2008, , 179-191.		0
435	Plasma membrane phospholipid labeling to estimate tumor burden and kinetics. Cancer Biology and Therapy, 2008, 7, 748-749.	3.4	0
436	Evolutionary Dynamics of Mutations in Hematopoietic Stem Cells and Beyond. , 2012, , 115-123.		0
437	Response to the Editor: On the Growth of Hematopoietic Stem Cells and Childhood Leukemias. Stem Cells, 2016, 34, 2610-2610.	3.2	0
438	Computational and systems biology of cancer. Computational and Systems Oncology, 2021, 1, e1005.	1.5	0
439	Epstein Barr Virus–Negative Lymphoplasmacytic Proliferation Limited to the Renal Allograft: A Unique Presentation of a Rare Disease. Kidney International Reports, 2021, 6, 2223-2227.	0.8	0
440	Prognostic Diversity of Cytogenetic Lesions in Myelofibrosis with Myeloid Metaplasia: A Prospective Study of 88 Patients Blood, 2004, 104, 1508-1508.	1.4	0
441	Oncolytic Measles Virus Selectively Targets CD46 Overexpression on Myeloma Cells Blood, 2004, 104, 2392-2392.	1.4	0
442	Presence of Unfavorable Cytogenetic Abnormalities Is the Strongest Predictor of Poor Survival in Secondary Myelofibrosis Blood, 2005, 106, 2585-2585.	1.4	0
443	Microcytosis in Myelofibrosis with Myeloid Metaplasia: Prevalence and Clinical Correlates Blood, 2005, 106, 4947-4947.	1.4	0
444	Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Transplanted for Multiple Myeloma Blood, 2005, 106, 1165-1165.	1.4	0
445	Single Versus Multiple Transplants for Multiple Myeloma: Insights from In Vivo and In Silico Studies Blood, 2006, 108, 5452-5452.	1.4	0
446	The Serum M-Spike and Transplant Outcome in Patients with Multiple Myeloma Blood, 2006, 108, 5441-5441.	1.4	0
447	Monocytosis Is an Independent Risk Factor for Survival in Agnogenic Myeloid Metaplasia Blood, 2006, 108, 3629-3629.	1.4	0
448	Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma Blood, 2007, 110, 1181-1181.	1.4	0
449	Melphalan and Dexamethasone Is an Effective Therapy for Primary Systemic Amyloidosis Blood, 2007, 110, 3608-3608.	1.4	0
450	Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma Blood, 2007, 110, 1492-1492.	1.4	0

#	Article	IF	CITATIONS
451	Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT Blood, 2007, 110, 2995-2995.	1.4	0
452	Comparison of High-Dose Cyclophosphamide and Growth Factor with Growth Factor Alone for Mobilization of Stem Cells for Transplantation in Patients with Multiple Myeloma Blood, 2008, 112, 2301-2301.	1.4	0
453	Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma Blood, 2009, 114, 3884-3884.	1.4	0
454	Response to Salvage Therapies and Outcome of Patients with Multiple Myeloma Relapsing After Pomalidomide Therapy. Blood, 2010, 116, 1965-1965.	1.4	0
455	Collection of Stem Cell Early In the Disease Course of Multiple Myeloma Is Associated with Early Engraftment Blood, 2010, 116, 4518-4518.	1.4	0
456	Risk Score at Diagnosis and the Dynamics of Response to TKI Therapy In Chronic Myeloid Leukemia Blood, 2010, 116, 1236-1236.	1.4	0
457	Five-Year Follow-up of Randomized, Phase II Trial of Idiotype-Pulsed Dendritic Cell Vaccine with Adjuvant Cytokines In Plateau Phase and Post-Transplant Multiple Myeloma. Blood, 2010, 116, 1958-1958.	1.4	0
458	IDH Mutations and Trisomy 8 In Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood, 2010, 116, 4009-4009.	1.4	0
459	Stem Cell Transplant without Growth Factor In Multiple Myeloma: Engraftment Kinetics, Bacteremia, and Hospitalization Blood, 2010, 116, 3469-3469.	1.4	0
460	Relapse of POEMS Following Autologous Stem Cell Transplantation: A Single Center Experience. Blood, 2011, 118, 3101-3101.	1.4	0
461	Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy. Blood, 2011, 118, 2992-2992.	1.4	0
462	Matched Case Control Analysis Comparing Long Term Survival of Multiple Myeloma Patients Who Received Stem Cell Transplant with and without Idiotype-Pulsed Dendritic Cell Vaccine. Blood, 2011, 118, 636-636.	1.4	0
463	IgD Amyloidosis: An Unrecognized Entity. Blood, 2011, 118, 5079-5079.	1.4	0
464	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. Blood, 2012, 120, 448-448.	1.4	0
465	Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM). Blood, 2012, 120, 600-600.	1.4	0
466	Refinement in Patient Selection to Reduce Treatment-Related Mortality From Stem Cell Transplantation in Amyloidosis. Blood, 2012, 120, 599-599.	1.4	0
467	Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2012, 120, 1988-1988.	1.4	0
468	Familial Myeloid Neoplasms: Clinical Spectrum and Associated Abnormalities. Blood, 2013, 122, 2794-2794.	1.4	0

#	Article	IF	CITATIONS
469	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. Blood, 2013, 122, 1979-1979.	1.4	0
470	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. Blood, 2013, 122, 3209-3209.	1.4	0
471	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). Blood, 2015, 126, 3292-3292.	1.4	0
472	Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial. Blood, 2015, 126, 3039-3039.	1.4	0
473	AL Amyloidosis and Patient Reported Quality of Life. Blood, 2015, 126, 3317-3317.	1.4	0
474	The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. Blood, 2015, 126, 3044-3044.	1.4	0
475	The impact of novel induction regimens on transplant outcome in newly diagnosed multiple myeloma after controlling for high-risk FISH cytogenetics Journal of Clinical Oncology, 2016, 34, 8033-8033.	1.6	0
476	Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma Journal of Clinical Oncology, 2016, 34, 8053-8053.	1.6	0
477	Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma Journal of Clinical Oncology, 2016, 34, 8017-8017.	1.6	0
478	Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes Journal of Clinical Oncology, 2016, 34, 8062-8062.	1.6	0
479	Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival Journal of Clinical Oncology, 2016, 34, 8016-8016.	1.6	0
480	A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. Blood, 2016, 128, 996-996.	1.4	0
481	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. Blood, 2016, 128, 3273-3273.	1.4	0
482	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. Blood, 2016, 128, 3251-3251.	1.4	0
483	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. Blood, 2016, 128, 1810-1810.	1.4	0
484	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. Blood, 2016, 128, 3306-3306.	1.4	0
485	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. Blood, 2016, 128, 1194-1194.	1.4	0
486	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. Blood, 2016, 128, 3269-3269.	1.4	0

#	Article	IF	CITATIONS
487	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 3338-3338.	1.4	0
488	Outcome of Very Young (≤40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. Blood, 2016, 128, 5576-5576.	1.4	0
489	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. Blood, 2016, 128, 2187-2187.	1.4	0
490	Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. Blood, 2016, 128, 2267-2267.	1.4	0
491	Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry. Blood, 2018, 132, 1038-1038.	1.4	0
492	Long-Term Survivorship with Active Multiple Myeloma. Blood, 2018, 132, 1912-1912.	1.4	0
493	Comparative Analysis of Staging Systems in AL Amyloidosis. Blood, 2018, 132, 3228-3228.	1.4	0
494	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	1.4	0
495	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. Blood, 2018, 132, 2147-2147.	1.4	0
496	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. Blood, 2018, 132, 3226-3226.	1.4	0
497	Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. Blood, 2018, 132, 4613-4613.	1.4	0
498	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). Blood, 2018, 132, 4502-4502.	1.4	0
499	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. Blood, 2018, 132, 5594-5594.	1.4	0
500	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. Blood, 2018, 132, 3227-3227.	1.4	0
501	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. Blood, 2018, 132, 5610-5610.	1.4	0
502	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2018, 132, 3268-3268.	1.4	0
503	Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. Blood, 2018, 132, 3436-3436.	1.4	0
504	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2018, 132, 4615-4615.	1.4	0

#	Article	IF	CITATIONS
505	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. Blood, 2019, 134, 4505-4505.	1.4	0
506	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). Blood, 2019, 134, 5523-5523.	1.4	0
507	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. Blood, 2019, 134, 1532-1532.	1.4	0
508	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. Blood, 2019, 134, 3080-3080.	1.4	0
509	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 5833-5833.	1.4	0
510	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. Blood, 2019, 134, 1904-1904.	1.4	0
511	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. Blood, 2019, 134, 5532-5532.	1.4	0
512	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 2197-2197.	1.4	0
513	Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience. Blood, 2019, 134, 2013-2013.	1.4	0
514	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. Blood, 2021, 138, 2707-2707.	1.4	0
515	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 ( VSV-IFNβ-NIS). Blood, 2021, 138, 1333-1333.	1.4	0
516	Prognostic Role of IL-6 in POEMS Syndrome. Blood, 2021, 138, 2700-2700.	1.4	0
517	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio ≥100. Blood, 2021, 138, 1617-1617.	1.4	0
518	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. Blood, 2021, 138, 3805-3805.	1.4	0
519	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. Blood, 2021, 138, 3773-3773.	1.4	0
520	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. Blood, 2021, 138, 3761-3761.	1.4	0
521	Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. Blood, 2021, 138, 1632-1632.	1.4	0
522	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. Blood, 2021, 138, 1619-1619.	1.4	0

#	Article	IF	CITATIONS
523	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. Blood, 2021, 138, 543-543.	1.4	Ο
524	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. Blood, 2021, 138, 1630-1630.	1.4	0
525	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. Blood, 2021, 138, 119-119.	1.4	0
526	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. Blood, 2021, 138, 2650-2650.	1.4	0
527	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. Blood, 2020, 136, 27-28.	1.4	0
528	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. Blood, 2020, 136, 44-45.	1.4	0
529	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. Blood, 2020, 136, 15-16.	1.4	0
530	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. Blood, 2020, 136, 14-15.	1.4	0
531	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. Blood, 2020, 136, 6-7.	1.4	0
532	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. Blood, 2020, 136, 21-22.	1.4	0
533	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 21-22.	1.4	0
534	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents. Blood, 2020, 136, 12-13.	1.4	0
535	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. Blood, 2020, 136, 37-38.	1.4	0
536	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Blood, 2020, 136, 41-42.	1.4	0
537	Clinical Burden of Paroxysmal Nocturnal Hemoglobinuria Among Patients Receiving C5 Inhibitors in the United States. Blood, 2020, 136, 2-2.	1.4	0
538	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. Bone Marrow Transplantation, 2022, , .	2.4	0